CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at Wedbush

CytomX Therapeutics (NASDAQ:CTMX) had its target price raised by equities researchers at Wedbush from $6.00 to $11.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s target price points to a potential upside of 62.96% from the company’s current price.

Several other brokerages also recently commented on CTMX. Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a report on Monday. Piper Sandler boosted their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Barclays upped their price objective on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $7.00 to $12.00 in a research note on Monday. Finally, HC Wainwright lifted their target price on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX opened at $6.75 on Tuesday. The stock has a market capitalization of $1.14 billion, a P/E ratio of 16.88 and a beta of 2.44. The business has a 50-day moving average of $5.24 and a two-hundred day moving average of $4.07. CytomX Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a net margin of 24.66% and a return on equity of 44.49%. The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. As a group, research analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTMX. Seven Fleet Capital Management LP acquired a new position in CytomX Therapeutics in the 4th quarter valued at approximately $208,000. Empowered Funds LLC bought a new stake in shares of CytomX Therapeutics in the 4th quarter worth approximately $133,000. XTX Topco Ltd grew its holdings in shares of CytomX Therapeutics by 63.9% during the 4th quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 18,705 shares in the last quarter. Virtus Investment Advisers LLC bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $270,000. Finally, Twinbeech Capital LP bought a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $75,000. 67.77% of the stock is currently owned by institutional investors.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 dose‑expansion data for Varsetatug (Varseta‑M) showed dose response with confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and a manageable safety profile—findings the company says support mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Positive Data Release
• Positive Sentiment: Market and media coverage amplified the data’s impact, highlighting response rates and estimated PFS that catalyzed the intraday rally as investors price in Varseta‑M’s late‑line CRC potential. Stock Market Today: CytomX Surges After Positive Data
• Positive Sentiment: Wall Street turned more bullish: JPMorgan upgraded CTMX to overweight with a $12 PT and HC Wainwright raised its PT to $17 (buy). A Seeking Alpha upgrade and note model a high risk‑adjusted NPV tied to Varseta‑M, supporting upside expectations if registrational plans advance. Seeking Alpha Upgrade & Analysis
• Neutral Sentiment: Pipeline development updates: CytomX is initiating combination studies (bevacizumab combo underway; chemo combo planned by end‑2026) and is seeking FDA alignment—progressive but timing and registrational design remain uncertain. 2025 Results and Business Update
• Negative Sentiment: CytomX launched a proposed underwritten public offering of $250M of common stock (and pre‑funded warrants for certain investors), which can provide runway but also raises near‑term dilution risk—a key watch for holders. Proposed Public Offering Announcement
• Negative Sentiment: Q4 results missed expectations: CTMX reported a larger‑than‑expected loss (EPS miss) and revenues well below estimates, which contrasts with the clinical upside and could pressure sentiment if funding/dilution concerns intensify. Zacks: Q4 Loss and Revenue Miss

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.